Gary Ingenito - 21 Jun 2022 Form 4 Insider Report for CATALYST PHARMACEUTICALS, INC. (CPRX)

Role
Chief Medical & Reg. Officer
Signature
/s/ Gary Ingenito
Issuer symbol
CPRX
Transactions as of
21 Jun 2022
Net transactions value
-$369,824
Form type
4
Filing time
23 Jun 2022, 17:02:37 UTC
Previous filing
16 Feb 2022
Next filing
16 Sep 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CPRX Common stock, par value $0.001 per share Options Exercise $594,092 +143,848 +652% $4.13 165,901 21 Jun 2022 Direct
transaction CPRX Common stock, par value $0.001 per share Sale $948,678 -143,848 -87% $6.60 22,053 21 Jun 2022 Direct F1, F2
transaction CPRX Common stock, par value $0.001 per share Options Exercise $25,408 +6,152 +28% $4.13 28,205 22 Jun 2022 Direct
transaction CPRX Common stock, par value $0.001 per share Sale $40,646 -6,152 -22% $6.61 22,053 22 Jun 2022 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CPRX Options to purchase common stock Options Exercise $0 -143,848 -12% $0.000000 1,077,819 21 Jun 2022 Common Stock 143,848 $4.13 Direct F4
transaction CPRX Options to purchase common stock Options Exercise $0 -6,152 -0.57% $0.000000 1,071,667 22 Jun 2022 Common Stock 6,152 $4.13 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Dr. Ingenito sold the shares on the open market for personal reasons and not as a result of any disagreement with the Registrant. Dr. Ingenito remains an officer of the Company.
F2 Shares were sold in various lots from $6.55 to $6.68 per share. The listed sale price represents a weighted average price for the shares sold.
F3 Shares were sold in various lots from $6.55 to $6.71 per share. The listed sale price represents a weighted average price for the shares sold.
F4 Options vested in three annual tranches beginning on June 30, 2016.